Cullinan Associates Inc. Sells 1,950 Shares of Stryker Corporation $SYK

Cullinan Associates Inc. cut its holdings in Stryker Corporation (NYSE:SYK) by 22.8% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,595 shares of the medical technology company’s stock after selling 1,950 shares during the period. Cullinan Associates Inc.’s holdings in Stryker were worth $2,167,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after purchasing an additional 133,892 shares during the period. State Street Corp increased its stake in Stryker by 2.1% during the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after acquiring an additional 311,507 shares during the period. Geode Capital Management LLC raised its holdings in Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after acquiring an additional 69,851 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after purchasing an additional 1,198,665 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the period. Institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on SYK shares. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a report on Friday, May 1st. Wells Fargo & Company decreased their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Citigroup dropped their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Finally, Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $392.87.

Stryker Price Performance

SYK traded up $2.75 on Friday, reaching $329.86. The stock had a trading volume of 2,724,614 shares, compared to its average volume of 2,471,298. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $126.46 billion, a price-to-earnings ratio of 38.18, a price-to-earnings-growth ratio of 2.11 and a beta of 0.77. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The firm has a 50-day moving average of $310.12 and a 200-day moving average of $337.97.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.